WuXi AppTec, a leading global pharmaceutical CRDMO, has received Frost & Sullivan's 2026 Global Company of the Year Recognition in the CRDMO industry for the tenth consecutive year.
Frost & Sullivan highlighted WuXi AppTec's integrated CRDMO model, which enables the company to support customers across the full drug development lifecycle, from early discovery through commercial manufacturing. The firm noted WuXi AppTec's global capacity, operational consistency, and ability to adapt to increasingly complex modalities as key differentiators.
"WuXi AppTec distinguishes itself through its strong focus on evolving customer needs," said Unmesh Lal, Vice President of Healthcare and Life Sciences at Frost & Sullivan. "Its commitment to customer success reinforces its position as a trusted partner to biopharmaceutical innovators worldwide."
"We are honored that Frost & Sullivan has once again recognized what our teams deliver every day for customers," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "As a dedicated enabler of the pharmaceutical industry, we remain committed to our CRDMO strategy and to helping customers around the world bring life-changing therapies to patients faster."